ArticleBJR artificial intelligence2026
AI-BLADE toolbox: AI-powered BLADdEr multiparametric MRI analysis for clinical application.
Article in BJR artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A two-stage foundation model for bladder tumor segmentation: An international multi-site studyEuropean journal of radiology artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Objectives: There is a growing need to develop user-friendly, bladder-specific image analysis tools that can produce reliable artificial intelligence (AI)-quantitative imaging biomarkers (QIBs) derived from multiparametric (mp)MRI data for clinical applications. To address it, we developed an AI-powered BLADdEr multiparametric MRI Analysis for Clinical Application (AI-BLADE, current release v1.0) toolbox designed for extracting mpMRI-derived quantitative metrics. Methods: AI-BLADE is an advanced tool for bladder-specific mpMRI data analysis with 2 core functionalities: (1) Deep Feature Analysis (MRI-DFA toolkit) and (2) Data-Driven Model-Based Analysis (MRI-MBA toolkit). AI-BLADE offers customizable options and serves as a one-stop shop solution for bladder cancer (BCa) clinical applications. The models within DFA and MBA were tested separately on 2 patient cohorts. DFA was used to classify BCa histology subtypes ( Results: Out of the 17 AI models tested, the VGG19 model with a decision tree classifier and no feature selection for the fully connected layer 7 achieved the highest area under the curve of the receiver operating characteristic of 0.79 in classifying BCa histology subtypes, demonstrating the strongest performance. The mean ADC and K Conclusion: The AI-BLADE (v1.0), a flexible and user-friendly software toolbox for analysing mpMRI data, shows strong potential for application in BCa oncology, offering capabilities that can enhance diagnostic accuracy and support improved patient outcomes. Advances in knowledge: This is the first study to design, develop, and implement a novel bladder-specific AI toolbox for analysing mpMRI data. AI-BLADE enables an advanced image analysis workflow, facilitating AI-QIB-based clinical decision-making for patients with BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.